Article - 13/09/2016 Catalent – galenics experts from Schorndorf Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
Press release - 20/06/2022 Protein changes in the liquor indicate inflammatory processes in the brain Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https://www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Press release - 19/10/2009 New ulcerative colitis therapy in sight Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Article - 11/03/2013 PHAST GmbH: firm focus on growth strategy Since August last year, PHAST Development GmbH & Co. KG has been bringing a breath of fresh air to the old research campus of the pharmaceutical company Takeda (formerly Nycomed) in Konstanz. The pharmaceutical company, with its roots in the city of Homburg, Germany, is a specialist in innovative methods for testing the quality of medicines. Amongst other things, PHAST develops test methods that enable the optimisation of drug release. A…https://www.gesundheitsindustrie-bw.de/en/article/news/phast-gmbh-firm-focus-on-growth-strategy
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Press release - 05/11/2014 Orphan drug status for Synovo's immune modulator SYD003 The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Synovo's investigational compound SYD003, a first in class tumour-targeted immune modulator.https://www.gesundheitsindustrie-bw.de/en/article/press-release/orphan-drug-status-for-synovo-s-immune-modulator-syd003
Press release - 14/07/2016 Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines
Press release - 13/11/2009 Single molecules under the laser: How the genetic material is unwrapped The genetic material found in cells is not in its free state, but is bound to large protein complexes and tightly wrapped. To activate genes that could well play a role in carcinogenesis, the genetic material first needs to be unwrapped and made accessible to other cell components. Using a new biophysical method called single molecule spectroscopy, scientists from the “Biophysics of Macromolecules” division at the German Cancer Research Centre…https://www.gesundheitsindustrie-bw.de/en/article/press-release/single-molecules-under-the-laser-how-the-genetic-material-is-unwrapped
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Article - 25/02/2013 Molecular monitoring of premature infants Premature births are not uncommon in Germany where around seven percent of newborns are born before week 37 of pregnancy. The WHO estimates that the numbers of preterm births are growing due to the increasing age of mothers. Doctors caring for the tiny patients are faced with a dilemma because regular blood samples required for the clinical monitoring of important blood parameters cannot be taken due to the infants low body volume.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-monitoring-of-premature-infants
Article - 30/05/2011 Technology Licensing Office (TLB): invention and patent management The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
Press release - 28/07/2009 New trachea made from human tissue A team of doctors from the Schillerhöhe Hospital, which is part of the Robert Bosch Hospital in Stuttgart, in cooperation with researchers from the Fraunhofer Institute of Interfacial Engineering and Biotechnology IGB in Stuttgart, has developed a method that enables artificially produced autologous tissue to be implanted into patients with severe tracheal injuries. The method involves the cultivation of extensive parts of the human trachea and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-trachea-made-from-human-tissue
Alternative to animal experiments - 21/03/2018 Drug tests using miniature organs At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-tests-using-miniature-organs
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 15/04/2010 Nycomed and Baxter receive FDA approval for TachoSil® Today Nycomed and its partner Baxter International Inc. NYSE BAX received the approval for TachoSil a surgical patch from the US Food and Drug Administration FDA. TachoSil has been approved as an adjunct to haemostasis control of bleeding in cardiovascular surgery. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-baxter-receive-fda-approval-for-tachosil
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 02/08/2010 Stephanie Combs – excellent research on the treatment of brain tumours Dr. Stephanie Combs radiooncologist at the University of Heidelberg was awarded the Hermann Holthusen Prize for her achievements in improving the treatment of malignant brain tumours. The prize which comes with a purse of 5000 euros is the most prestigious prize in the field of radiooncology in Germany. Dr. Combs received the prize from the German Society of Radiooncology DEGRO at its annual meeting held in Magdeburg in June 2010. Dr. Combs most…https://www.gesundheitsindustrie-bw.de/en/article/press-release/stephanie-combs-excellent-research-on-the-treatment-of-brain-tumours
Company profile - 27/06/2016 Atriva Therapeutics GmbH: new ways to treat influenza Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
Article - 05/02/2008 Protecting the liver from oxygen stress The Emmy Noether junior research group in the Department of Surgery at the University Hospital of Heidelberg is to be funded with 1.2 million over the next five years. The group will focus on how tissue damage in donor livers can be prevented. The group headed by Dr. Martin Schneider.https://www.gesundheitsindustrie-bw.de/en/article/news/protecting-the-liver-from-oxygen-stress
Article - 12/09/2016 New target for the therapy of hepatocellular carcinoma discovered Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells. https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
Press release - 18/02/2010 New molecules promise improved diagnosis of pancreatic cancer Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer